Fennec Pharmaceuticals Inc.
FENCHealthcare|Biotechnology|US
$9.81
+0.42 (+4.47%)
Tangible Book / Share
$1.23
Cash / Share
$1.19
About
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Stock Price
+22.6%(1Y)
1M
-7.7%
3M
-15.3%
6M
+41.6%
YTD
+27.4%
1Y
+27.7%
3Y
+28.7%
5Y
+5.4%
Pipeline Summary
2 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Available: 1Recruiting: 1
Active Trials (1)
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
NCT07407582Solid Tumor Malignancies
Phase 1Phase 2Recruiting
Enrollment: 25 participants
Key Facts
Market Cap$344.0M
Employees35 (+9% YoY)
CEOJeffrey S. Hackman
IPO DateSep 15, 2017
Beta1.21
52-Week Range$5.65 – $13.25
Avg Volume176,677
ExchangeNASDAQ
Websitefennecpharma.com
Ownership
Float48.4%
Shares Outstanding35.1M
Recent Insider Trades
Evans Terry LAWARD
Oct 31, 2026168 shares
Sayad Pierre SargisAWARD
Oct 31, 2026168 shares
Hackman Jeffrey S.AWARD
Oct 31, 20261,159 shares
Cioffi Christiana MarieAWARD
Oct 31, 2026156 shares
Andrade RobertAWARD
Oct 31, 20261,703 shares
Peers
AARDAardvark Therapeutics, Inc. Common Stock
$25.6MAVTXAvalo Therapeutics, Inc.
$371.7MBDTXBlack Diamond Therapeutics, Inc.
$99.4MCRBUCaribou Biosciences, Inc.
$48.1MENTAEnanta Pharmaceuticals, Inc.
$320.4MEPRXEupraxia Pharmaceuticals Inc.
$455.2MNAUTNautilus Biotechnolgy, Inc.
$284.0MOBIOOrchestra BioMed Holdings, Inc.
$341.4MRecent News
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
Nov 6, 2026 · globenewswire.com
Adherex Technologies Inc. (NASDAQ:FENC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Oct 18, 2026 · defenseworld.net
Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey
Sep 28, 2026 · defenseworld.net
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Sep 17, 2026 · globenewswire.com
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
Aug 12, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:10 AM